Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
NEW YORK – 858 Therapeutics on Thursday said it raised $50 million in a Series B financing round to advance its pipeline of small molecule therapeutics, including the poly (ADP) ribose glycohydrolase ...
In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
NEW YORK – ReCode Therapeutics on Thursday said it has treated the first cystic fibrosis patient with its inhaled messenger RNA (mRNA) therapy within a Phase Ib trial. Investigators will assess the ...
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...